Stocks › EDIT
Editas Medicine, Inc.
EDIT·Nasdaq·
United States·USD
United States·USD$2.75
+0.02 (+0.73%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
EDIT
Editas Medicine, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
EDITS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of EDIT by members of U.S. Congress · 17 on record
Whale Activity
Position changes in EDIT reported for 2026-06-30 by 12 tracked institutional filers
- Increased4
- New1
- Held0
- Decreased4
- Closed0
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.6M | $34.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $19.9M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.6M | $11.7M | increased |
| GordonMD Global Investments LP | 3.1M | $10.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | 2.5M | $8.0M | decreased |
| D. E. Shaw & Co., Inc. | 1.9M | $6.2M | decreased |
| TWO SIGMA INVESTMENTS, LP | 1.3M | $4.3M | decreased |
| Seven Fleet Capital Management LP | 1.3M | $4.3M | — |
| MILLENNIUM MANAGEMENT LLC | 499.0K | $1.6M | new |
| Casdin Capital, LLC | 445.0K | $1.4M | — |
| CITADEL ADVISORS LLC | 212.8K | $689K | decreased |
| Point72 Asset Management, L.P. | 125.2K | $406K | increased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by EDIT insiders, by quarter · Form 4
Recent Insider Transactions
391 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Parison AmySVP, Chief Financial Officer | Sale | −453 | $3.04 | $1K | Sep 3, 2026 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −709 | $3.04 | $2K | Sep 3, 2026 | Form 4 ↗ |
| O'Neill Gilmore NeilCEO · Director | Sale | −5,124 | $3.04 | $16K | Sep 3, 2026 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −678 | $2.58 | $2K | Aug 3, 2026 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −4,928 | $2.67 | $13K | Jul 28, 2026 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −464 | $2.70 | $1K | Jun 3, 2026 | Form 4 ↗ |
| O'Neill Gilmore NeilCEO · Director | Sale | −15.4K | $2.70 | $42K | Jun 3, 2026 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −731 | $2.70 | $2K | Jun 3, 2026 | Form 4 ↗ |
| O'Neill Gilmore NeilCEO · Director | Sale | −5,394 | $2.02 | $11K | Mar 3, 2026 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −474 | $2.02 | $957 | Mar 3, 2026 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −749 | $2.02 | $2K | Mar 3, 2026 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −713 | $2.15 | $2K | Dec 3, 2025 | Form 4 ↗ |
| O'Neill Gilmore NeilCEO · Director | Sale | −5,603 | $2.15 | $12K | Dec 3, 2025 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −461 | $2.15 | $991 | Dec 3, 2025 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −710 | $2.60 | $2K | Sep 3, 2025 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −458 | $2.60 | $1K | Sep 3, 2025 | Form 4 ↗ |
| O'Neill Gilmore NeilCEO · Director | Sale | −5,592 | $2.60 | $15K | Sep 3, 2025 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −679 | $2.58 | $2K | Aug 7, 2025 | Form 4 ↗ |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sale | −5,121 | $2.49 | $13K | Jul 31, 2025 | Form 4 ↗ |
| Parison AmySVP, Chief Financial Officer | Sale | −446 | $1.72 | $767 | Jun 3, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding EDIT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.9M | $15.8M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.6M | $8.5M | 0.01% | Jun 30, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 2.0M | $6.6M | 0.05% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 1.7M | $5.0M | 0.13% | Apr 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $3.6M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.1M | $2.8M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 844.0K | $2.7M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 687.5K | $2.2M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 509.4K | $1.8M | 0.00% | May 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 505.3K | $1.7M | 0.01% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list EDIT's shares (CUSIP 28106W103), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Daniel SchneebergerSCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Aug 14, 2026 · ↗ - ADAR1 Capital Management, LLCSCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Aug 14, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 8.4M shares5.0%
Jul 29, 2026 · ↗ - RA Capital Healthcare Fund, L.P.SCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Jun 3, 2026 · ↗ - Rajeev ShahSCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Jun 3, 2026 · ↗ - Peter KolchinskySCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Jun 3, 2026 · ↗ - RA Capital Management, L.P.SCHEDULE 13G · passive (13G) · 8.9M shares5.8%
Jun 3, 2026 · ↗ - Chen YuSCHEDULE 13G · passive (13G) · 15.8M shares9.9%
Jun 3, 2026 · ↗ - TCG Crossover Fund III, L.P.SCHEDULE 13G · passive (13G) · 15.8M shares9.9%
Jun 3, 2026 · ↗ - TCG Crossover GP III, LLCSCHEDULE 13G · passive (13G) · 15.8M shares9.9%
Jun 3, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming editas medicine as client
No lobbying filings found naming Editas Medicine, Inc. as the client.
- THE NICKLES GROUP, LLCEDITAS MEDICINE · 2020 Q2 · MMM, HCR$10K
Filing ↗ - THE NICKLES GROUP, LLCEDITAS MEDICINE · 2020 Q1 · HCR, MMM$50K
Filing ↗ - THE NICKLES GROUP, LLCEDITAS MEDICINE · 2019 Q4 · HCR, MMM$50K
Filing ↗ - THE NICKLES GROUP, LLCEDITAS MEDICINE · 2019 Q3 · HCR, MMM$50K
Filing ↗ - THE NICKLES GROUP, LLCEDITAS MEDICINE · 2019 Q2 · MMM, HCR$50K
Filing ↗
Government Contracts
Federal awards to Editas Medicine, Inc. · USAspending
No federal contract awards found for Editas Medicine, Inc..
U.S. Patents
Recent USPTO applications naming Editas Medicine, Inc.
No USPTO patent applications found for Editas Medicine, Inc..
Annual Financials
From EDIT's 10-K filings · XBRL
No annual XBRL figures on record for EDIT. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in EDIT's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 5.02, 9.01Results of operations · Officer / director changeAug 5, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 18, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 26, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsMay 26, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 26, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 14, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About Editas Medicine, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001650664 ↗